ODTX.US Odyssey Therapeutics, Inc. Common Stock
- Market cap
- USD 920M
- P/E
- -
- P/B
- 2.45x
- ROE
- -51.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ODTX.US undervalued?
Graham numberThe Graham number of Odyssey Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Odyssey Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Odyssey Therapeutics, Inc. Common Stock yet.
Odyssey Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (…
Full company profileOdyssey Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Odyssey Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 1.04M | 4.47M | 2.98M | 0.00 |
| Gross Profit | - | - | - | 2.98M | - |
| Operating Income | -123M | -133M | -135M | -161M | -198M |
| EBITDA | -121M | -120M | -124M | -145M | -188M |
| Net Income | -125M | -126M | -129M | -149M | -192M |
| EPS | -2.64 | -2.67 | -2.74 | -3.15 | -4.01 |
| Balance Sheet | |||||
| Total Assets | 317M | 287M | 197M | 270M | 438M |
| Total Liabilities | 462M | 549M | 580M | 758M | 62.3M |
| Shareholders' Equity | -145M | -263M | -383M | -488M | 376M |
| Cash & Short-term Investments | 241M | 52.5M | 59.1M | 181M | 326M |
| Total Debt | - | - | - | 27.1M | 23.5M |
| Cash Flow | |||||
| Operating Cash Flow | -99.8M | -113M | -117M | -129M | -156M |
| Capital Expenditure | 13.0M | 5.06M | 764K | 1.23M | 1.12M |
| Free Cash Flow | -113M | -118M | -118M | -131M | -157M |
| Ratios | |||||
| ROE | - | - | - | - | -51.1% |
| ROA | -39.3% | -44.0% | -65.5% | -55.1% | -43.9% |
| Net Profit Margin | - | -12,144.5% | -2,891.8% | -4,994.9% | - |
| Debt to Equity | - | - | - | - | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Odyssey Therapeutics, Inc. Common Stock dividends
Odyssey Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Odyssey Therapeutics, Inc. Common Stock
- Insiders 6.19%
- Institutions 89.09%
- Public & others 4.72%
- Shares outstanding 48.1M
- Free float 23.7M
Top funds holding ODTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.10M | 2.30% | +6.85% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 531K | 1.10% | 0.00% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 508K | 1.06% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 413K | 0.86% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 373K | 0.78% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 341K | 0.71% | +0.35% | Aug 2026 |
| Fidelity Growth Company K6 | 309K | 0.64% | +7.00% | Aug 2026 |
| Fidelity Series Growth Company | 267K | 0.55% | +7.03% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 175K | 0.36% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 99.8K | 0.21% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 96.4K | 0.20% | +711.50% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 91.9K | 0.19% | -0.38% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 83.7K | 0.17% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 74.1K | 0.15% | -2.94% | Sep 2026 |
| abrdn Healthcare Investors | 64.2K | 0.13% | +131.78% | Oct 2026 |
| iShares Russell 2000 Value ETF | 58.9K | 0.12% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 50.2K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 49.0K | 0.10% | +74.73% | Aug 2026 |
| Schwab Small Cap Index | 40.1K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 33.0K | 0.07% | -0.05% | Sep 2026 |
Top institutions holding ODTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 5.18M | 10.78% | 0.00% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 3.79M | 7.89% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 3.69M | 7.68% | 0.00% | Jun 2026 |
| Lightspeed Management Co LLC | 3.61M | 7.51% | 0.00% | Sep 2026 |
| Orbimed Advisors LLC | 3.00M | 6.24% | 0.00% | Jun 2026 |
| Sanofi | 1.99M | 4.14% | -0.09% | Sep 2026 |
| Deerfield Management Co | 1.05M | 2.18% | 0.00% | Jun 2026 |
| Sands Capital Ventures, LLC | 875K | 1.82% | 0.00% | Sep 2026 |
| Hillhouse Capital Advisors, Ltd. | 832K | 1.73% | 0.00% | Jun 2026 |
| General Catalyst Group Management, LLC | 810K | 1.69% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 766K | 1.59% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 725K | 1.51% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 720K | 1.50% | 0.00% | Jun 2026 |
| Foresite Capital Management V, LLC | 713K | 1.48% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 575K | 1.20% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 556K | 1.16% | 0.00% | Jun 2026 |
| Logos Global Management LP | 522K | 1.09% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 493K | 1.03% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 472K | 0.98% | 0.00% | Jun 2026 |
| Catalio Capital Management, LP | 458K | 0.95% | 0.00% | Jun 2026 |
Odyssey Therapeutics, Inc. Common Stock company profile
- Company name
- Odyssey Therapeutics, Inc. Common Stock
- Ticker
- ODTX.US
- Exchange
- USA Stocks
- Listed since
- May 8, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- 51 Sleeper Street, Boston, MA, United States, 02210
- Phone
- 617 865 9628
- Website
- odysseytx.com
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor"associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. Common Stock management
10- Dr. Gary D. Glick Ph.D.Founder, President, CEO & Director · born 1962
- Mr. Jason Haas M.B.A.Chief Financial Officer · born 1968
- Mr. Collin ToddSenior Vice President of Strategy & Business Development · born 1992
- Prof. Eicke Latz M.D., Ph.D.Scientific Co-Founder
- Dr. Kim Lewis Ph.D.Scientific Co-Founder
- Dr. Felix Meissner Ph.D.Scientific Co-Founder
- Dr. Florian.I Schmidt Ph.D.Scientific Co-Founder
- Ms. Jolie M. Siegel J.D.Executive VP, General Counsel & Secretary · born 1977
- Dr. Natalie Dales Ph.D.Chief of Research Operations & Portfolio Strategy · born 1970
- Dr. Joseph McDonald Ph.D.Chief Data Officer